Stitch123 personal page - To The Moon

Stitch123

Stitch123

No personal profile

19Follow

0Followers

0Topic

0Badge

2021-09-03

This move will get vaccination rate higher.

Sorry, the original content has been removed

2021-09-01

Yeah

Apple shares rose nearly 2% in early trading

2021-08-25

20yrs of effort just crumpled. Hopefully they can evacuate as many as possible.

Sorry, the original content has been removed

2021-03-12

Up & coming

Why Is Everyone Talking About Electric Vehicle Stocks?

2021-08-03

Selling down means opportunity to enter at a lower cost.

2021-03-05

The new norm

3 Medtech Trends That Will Outlive the Pandemic

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3561703528909824,"uuid":"3561703528909824","gmtCreate":1598620881723,"gmtModify":1615560363254,"name":"Stitch123","pinyin":"stitch123","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":19,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.05.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":815939203,"gmtCreate":1630634320902,"gmtModify":1676530361854,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"This move will get vaccination rate higher.&nbsp;","listText":"This move will get vaccination rate higher.&nbsp;","text":"This move will get vaccination rate higher.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815939203","repostId":"1174929803","repostType":4,"isVote":1,"tweetType":1,"viewCount":554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816504735,"gmtCreate":1630506089527,"gmtModify":1676530324278,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816504735","repostId":"1194937312","repostType":4,"repost":{"id":"1194937312","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630503428,"share":"https://ttm.financial/m/news/1194937312?lang=&edition=fundamental","pubTime":"2021-09-01 21:37","market":"us","language":"en","title":"Apple shares rose nearly 2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194937312","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% in early trading.\n\n\nWolfe Research upgrades Apple from Underperform to P","content":"<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/074074cd9456d4c1a7776d87b07c5c72\" tg-width=\"885\" tg-height=\"572\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li>Wolfe Research upgrades Apple&nbsp;from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.</li>\n <li>Analyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.</li>\n <li>Kvaal raises Apple's price target from $135 to $155.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-01 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/074074cd9456d4c1a7776d87b07c5c72\" tg-width=\"885\" tg-height=\"572\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li>Wolfe Research upgrades Apple&nbsp;from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.</li>\n <li>Analyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.</li>\n <li>Kvaal raises Apple's price target from $135 to $155.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194937312","content_text":"Apple shares rose nearly 2% in early trading.\n\n\nWolfe Research upgrades Apple from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.\nAnalyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.\nKvaal raises Apple's price target from $135 to $155.","news_type":1},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837961971,"gmtCreate":1629852922993,"gmtModify":1676530151000,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"20yrs of effort just crumpled. Hopefully they can evacuate as many&nbsp;as possible.&nbsp;","listText":"20yrs of effort just crumpled. Hopefully they can evacuate as many&nbsp;as possible.&nbsp;","text":"20yrs of effort just crumpled. Hopefully they can evacuate as many as possible.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837961971","repostId":"2162080258","repostType":4,"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804704853,"gmtCreate":1627978170272,"gmtModify":1703498970524,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Selling down means opportunity to enter at a lower cost.&nbsp;","listText":"Selling down means opportunity to enter at a lower cost.&nbsp;","text":"Selling down means opportunity to enter at a lower cost.","images":[{"img":"https://static.tigerbbs.com/2b864e019c07a34827c5582888f33272","width":"1080","height":"2449"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804704853","isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":328799706,"gmtCreate":1615557914205,"gmtModify":1704784522862,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Up &amp; coming","listText":"Up &amp; coming","text":"Up & coming","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328799706","repostId":"2118912950","repostType":4,"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367371362,"gmtCreate":1614915056156,"gmtModify":1704776938788,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"The new norm&nbsp;","listText":"The new norm&nbsp;","text":"The new norm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367371362","repostId":"1138978257","repostType":4,"repost":{"id":"1138978257","pubTimestamp":1614913165,"share":"https://ttm.financial/m/news/1138978257?lang=&edition=fundamental","pubTime":"2021-03-05 10:59","market":"us","language":"en","title":"3 Medtech Trends That Will Outlive the Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1138978257","media":"Nasdaq","summary":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the e","content":"<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.</p>\n<p>Neither are the solutions to those challenges.</p>\n<p>Innovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?</p>\n<p><b>Patient Safety</b></p>\n<p>While increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a&nbsp;report&nbsp;citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.</p>\n<p>Social distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.</p>\n<p>Medical communities have even cultivated awareness campaigns to streamline the issue, with projects like the&nbsp;Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.</p>\n<p>Publications such as the&nbsp;British Medical Journal&nbsp;had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.</p>\n<p><b>Telemedicine</b></p>\n<p>Telemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.</p>\n<p>In April of 2020, 43.5 percent of Medicare primary care visits&nbsp;utilized&nbsp;telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.</p>\n<p>Telemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.</p>\n<p>According&nbsp;to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.</p>\n<p><b>Deep Tech</b></p>\n<p>Digital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.</p>\n<p>Deeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.</p>\n<p>Swati Chaturvedi, CEO of Propel, put it succinctly in an&nbsp;interview&nbsp;with Medtech Innovation:</p>\n<p>“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”</p>\n<p>Deep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.</p>\n<p>It would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.</p>\n<p><i>About Author</i></p>\n<p><i>Doron Besser, Chief Executive Officer: Doron Besser is the CEO of&nbsp;ENvizion Medical&nbsp;and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.</i></p>\n<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Medtech Trends That Will Outlive the Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Medtech Trends That Will Outlive the Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 10:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138978257","content_text":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.\nNeither are the solutions to those challenges.\nInnovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?\nPatient Safety\nWhile increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a report citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.\nSocial distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.\nMedical communities have even cultivated awareness campaigns to streamline the issue, with projects like the Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.\nPublications such as the British Medical Journal had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.\nTelemedicine\nTelemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.\nIn April of 2020, 43.5 percent of Medicare primary care visits utilized telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.\nTelemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.\nAccording to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.\nDeep Tech\nDigital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.\nDeeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.\nSwati Chaturvedi, CEO of Propel, put it succinctly in an interview with Medtech Innovation:\n“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”\nDeep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.\nIt would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.\nAbout Author\nDoron Besser, Chief Executive Officer: Doron Besser is the CEO of ENvizion Medical and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":815939203,"gmtCreate":1630634320902,"gmtModify":1676530361854,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"This move will get vaccination rate higher.&nbsp;","listText":"This move will get vaccination rate higher.&nbsp;","text":"This move will get vaccination rate higher.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815939203","repostId":"1174929803","repostType":4,"isVote":1,"tweetType":1,"viewCount":554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816504735,"gmtCreate":1630506089527,"gmtModify":1676530324278,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816504735","repostId":"1194937312","repostType":4,"repost":{"id":"1194937312","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630503428,"share":"https://ttm.financial/m/news/1194937312?lang=&edition=fundamental","pubTime":"2021-09-01 21:37","market":"us","language":"en","title":"Apple shares rose nearly 2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194937312","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% in early trading.\n\n\nWolfe Research upgrades Apple from Underperform to P","content":"<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/074074cd9456d4c1a7776d87b07c5c72\" tg-width=\"885\" tg-height=\"572\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li>Wolfe Research upgrades Apple&nbsp;from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.</li>\n <li>Analyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.</li>\n <li>Kvaal raises Apple's price target from $135 to $155.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-01 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/074074cd9456d4c1a7776d87b07c5c72\" tg-width=\"885\" tg-height=\"572\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li>Wolfe Research upgrades Apple&nbsp;from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.</li>\n <li>Analyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.</li>\n <li>Kvaal raises Apple's price target from $135 to $155.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194937312","content_text":"Apple shares rose nearly 2% in early trading.\n\n\nWolfe Research upgrades Apple from Underperform to Peer Perform on strong iPhone 12 demand trends that should provide a tailwind for the iPhone 13 lineup expected to launch later this month.\nAnalyst Jeffrey Kvaal says the demand was driven by healthy U.S. operator promotions and Huawei share gains. Additional fuel is coming from the tech giant's supply chain strength, which partially offsets the global component shortage, and the \"elevated\" average selling prices.\nKvaal raises Apple's price target from $135 to $155.","news_type":1},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837961971,"gmtCreate":1629852922993,"gmtModify":1676530151000,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"20yrs of effort just crumpled. Hopefully they can evacuate as many&nbsp;as possible.&nbsp;","listText":"20yrs of effort just crumpled. Hopefully they can evacuate as many&nbsp;as possible.&nbsp;","text":"20yrs of effort just crumpled. Hopefully they can evacuate as many as possible.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837961971","repostId":"2162080258","repostType":4,"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328799706,"gmtCreate":1615557914205,"gmtModify":1704784522862,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Up &amp; coming","listText":"Up &amp; coming","text":"Up & coming","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328799706","repostId":"2118912950","repostType":4,"repost":{"id":"2118912950","pubTimestamp":1615555397,"share":"https://ttm.financial/m/news/2118912950?lang=&edition=fundamental","pubTime":"2021-03-12 21:23","market":"us","language":"en","title":"Why Is Everyone Talking About Electric Vehicle Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2118912950","media":"Motley Fool ","summary":"Could this be the next major growth market? Some investors think so.","content":"<p>Electric vehicles and related stocks have been some of the hottest on the market over the past year. <b>Tesla</b> (NASDAQ:TSLA) has surged to new highs, and newcomers like <b>Fisker</b> (NYSE:FSR), <b><a href=\"https://laohu8.com/S/BLNK\">Blink Charging</a></b> (NASDAQ:BLNK), <b>Nikola</b> (NASDAQ:NKLA), and others have either hit the market with multi-billion dollar valuations.</p>\n<p>Why are EVs such a hot market right now? In a word: growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/24b8adabd80fb45014728bc8ba843629\" tg-width=\"700\" tg-height=\"465\"><span>Image source: Getty Images.</span></p>\n<h2>The booming EV market</h2>\n<p>In 2011, about 45,000 electric vehicles were sold globally, according to data from the International Energy Agency (IEA). &nbsp;By 2020, sales of electric vehicles had ballooned to 3.24 million, according to estimates from ev-volumes.com. And that doesn't include sales from dozens of new models hitting the market in the next few years.</p>\n<p>A lot has changed in the last decade. Range anxiety has faded away as the number of vehicles with 300 miles or more in range is growing and the network of charging stations is proliferating. Meanwhile, costs are coming down and today it's (finally) nearly as cost effective to buy an EV as a traditional vehicle.</p>\n<p>Given these trends, investors are seeing an opportunity to disrupt the old, established players in the auto market.</p>\n<h2>Disrupting Detroit</h2>\n<p>A big part of the allure of EV upstarts is the enormous market they're entering. Just look at how <b>GM</b> (NYSE:GM), <b>Ford</b> (NYSE:F), <b>Honda</b> (NYSE:HMC), <b>Toyota</b> (NYSE:TM), and <b>Volkswagen</b> (OTC:VWAGY) dwarf a relatively established company like Tesla's revenue today. These five traditional auto companies generated over $800 billion in revenue over the past year, and any EV upstart that captures even a few percentage points of that market could be a huge success.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/492f4606a05448b2b38f853f7754f150\" tg-width=\"720\" tg-height=\"503\"><span>GM Revenue (TTM) data by YCharts</span></p>\n<p>There are reasons to be bullish on EVs and even EV start-ups. EVs <i>could</i> generate higher margins than internal combustion vehicles as costs come down. For start-ups, the opportunity to build a business without dealers engrained in the business model is another huge advantage. And the electrification of all things transportation may just be getting started.</p>\n<h2>The allure of autonomous driving</h2>\n<p>On top of the growth EVs have already demonstrated, investors see more potential for autonomous driving from EV companies than their Detroit rivals. Tesla has proven that people are willing to pay for autonomous driving technology as essentially software as a service. And most EV companies today are incorporating autonomous technology in <a href=\"https://laohu8.com/S/AONE\">one</a> form or another.</p>\n<p>The difficulty is figuring out the sustainability of autonomous software as a business for automakers. Tesla's early adopters are paying $10,000 for the \"Full Self-Driving\" option, and that sets a benchmark for others to follow. While it may take a while for companies to figure out how much autonomous driving technology is worth and how to make money off it, investors see this as an option to generate incrementally higher margin revenue off each sale. Tesla, GM, Rivian, and many others are including some self-driving features or driver assistance systems that investors see as another growth opportunity tied to EVs.</p>\n<h2>Will the euphoria continue?</h2>\n<p>Thus far, electric vehicle stocks have been living off the market's hype and projections about future growth. Highly valued companies like Fisker, Nikola, and Rivian haven't even generated revenue, much less a profit. But the rubber will hit the road soon.</p>\n<p>In the next three years, dozens of EV models will be released and legacy automakers will make their run at the market. <b>General Motors</b> (NYSE:GM) has said it will make only electric vehicles by 2035, and <b>VW</b> says 50% of its U.S. sales will be electric by 2030. Big auto is coming for the upstarts, and it could be a battle that defines the auto industry over the next decade.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Everyone Talking About Electric Vehicle Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Everyone Talking About Electric Vehicle Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-12 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/12/why-is-everyone-talking-about-electric-vehicle-sto/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Electric vehicles and related stocks have been some of the hottest on the market over the past year. Tesla (NASDAQ:TSLA) has surged to new highs, and newcomers like Fisker (NYSE:FSR), Blink Charging (...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/12/why-is-everyone-talking-about-electric-vehicle-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLNK":"Blink Charging","VWAGY":"大众汽车ADR","NKLA":"Nikola Corporation","FSR":"菲斯克","GM":"通用汽车","F":"福特汽车","TSLA":"特斯拉","HMC":"本田汽车","TM":"丰田汽车"},"source_url":"https://www.fool.com/investing/2021/03/12/why-is-everyone-talking-about-electric-vehicle-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118912950","content_text":"Electric vehicles and related stocks have been some of the hottest on the market over the past year. Tesla (NASDAQ:TSLA) has surged to new highs, and newcomers like Fisker (NYSE:FSR), Blink Charging (NASDAQ:BLNK), Nikola (NASDAQ:NKLA), and others have either hit the market with multi-billion dollar valuations.\nWhy are EVs such a hot market right now? In a word: growth.\nImage source: Getty Images.\nThe booming EV market\nIn 2011, about 45,000 electric vehicles were sold globally, according to data from the International Energy Agency (IEA).  By 2020, sales of electric vehicles had ballooned to 3.24 million, according to estimates from ev-volumes.com. And that doesn't include sales from dozens of new models hitting the market in the next few years.\nA lot has changed in the last decade. Range anxiety has faded away as the number of vehicles with 300 miles or more in range is growing and the network of charging stations is proliferating. Meanwhile, costs are coming down and today it's (finally) nearly as cost effective to buy an EV as a traditional vehicle.\nGiven these trends, investors are seeing an opportunity to disrupt the old, established players in the auto market.\nDisrupting Detroit\nA big part of the allure of EV upstarts is the enormous market they're entering. Just look at how GM (NYSE:GM), Ford (NYSE:F), Honda (NYSE:HMC), Toyota (NYSE:TM), and Volkswagen (OTC:VWAGY) dwarf a relatively established company like Tesla's revenue today. These five traditional auto companies generated over $800 billion in revenue over the past year, and any EV upstart that captures even a few percentage points of that market could be a huge success.\nGM Revenue (TTM) data by YCharts\nThere are reasons to be bullish on EVs and even EV start-ups. EVs could generate higher margins than internal combustion vehicles as costs come down. For start-ups, the opportunity to build a business without dealers engrained in the business model is another huge advantage. And the electrification of all things transportation may just be getting started.\nThe allure of autonomous driving\nOn top of the growth EVs have already demonstrated, investors see more potential for autonomous driving from EV companies than their Detroit rivals. Tesla has proven that people are willing to pay for autonomous driving technology as essentially software as a service. And most EV companies today are incorporating autonomous technology in one form or another.\nThe difficulty is figuring out the sustainability of autonomous software as a business for automakers. Tesla's early adopters are paying $10,000 for the \"Full Self-Driving\" option, and that sets a benchmark for others to follow. While it may take a while for companies to figure out how much autonomous driving technology is worth and how to make money off it, investors see this as an option to generate incrementally higher margin revenue off each sale. Tesla, GM, Rivian, and many others are including some self-driving features or driver assistance systems that investors see as another growth opportunity tied to EVs.\nWill the euphoria continue?\nThus far, electric vehicle stocks have been living off the market's hype and projections about future growth. Highly valued companies like Fisker, Nikola, and Rivian haven't even generated revenue, much less a profit. But the rubber will hit the road soon.\nIn the next three years, dozens of EV models will be released and legacy automakers will make their run at the market. General Motors (NYSE:GM) has said it will make only electric vehicles by 2035, and VW says 50% of its U.S. sales will be electric by 2030. Big auto is coming for the upstarts, and it could be a battle that defines the auto industry over the next decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804704853,"gmtCreate":1627978170272,"gmtModify":1703498970524,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"Selling down means opportunity to enter at a lower cost.&nbsp;","listText":"Selling down means opportunity to enter at a lower cost.&nbsp;","text":"Selling down means opportunity to enter at a lower cost.","images":[{"img":"https://static.tigerbbs.com/2b864e019c07a34827c5582888f33272","width":"1080","height":"2449"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804704853","isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":367371362,"gmtCreate":1614915056156,"gmtModify":1704776938788,"author":{"id":"3561703528909824","authorId":"3561703528909824","authorIdStr":"3561703528909824","name":"Stitch123","avatar":"https://static.tigerbbs.com/75e3fa44a61cf34d38fca9d42ca78e4a","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3561703528909824"},"themes":[],"htmlText":"The new norm&nbsp;","listText":"The new norm&nbsp;","text":"The new norm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367371362","repostId":"1138978257","repostType":4,"repost":{"id":"1138978257","pubTimestamp":1614913165,"share":"https://ttm.financial/m/news/1138978257?lang=&edition=fundamental","pubTime":"2021-03-05 10:59","market":"us","language":"en","title":"3 Medtech Trends That Will Outlive the Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1138978257","media":"Nasdaq","summary":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the e","content":"<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.</p>\n<p>Neither are the solutions to those challenges.</p>\n<p>Innovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?</p>\n<p><b>Patient Safety</b></p>\n<p>While increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a&nbsp;report&nbsp;citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.</p>\n<p>Social distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.</p>\n<p>Medical communities have even cultivated awareness campaigns to streamline the issue, with projects like the&nbsp;Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.</p>\n<p>Publications such as the&nbsp;British Medical Journal&nbsp;had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.</p>\n<p><b>Telemedicine</b></p>\n<p>Telemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.</p>\n<p>In April of 2020, 43.5 percent of Medicare primary care visits&nbsp;utilized&nbsp;telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.</p>\n<p>Telemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.</p>\n<p>According&nbsp;to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.</p>\n<p><b>Deep Tech</b></p>\n<p>Digital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.</p>\n<p>Deeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.</p>\n<p>Swati Chaturvedi, CEO of Propel, put it succinctly in an&nbsp;interview&nbsp;with Medtech Innovation:</p>\n<p>“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”</p>\n<p>Deep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.</p>\n<p>It would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.</p>\n<p><i>About Author</i></p>\n<p><i>Doron Besser, Chief Executive Officer: Doron Besser is the CEO of&nbsp;ENvizion Medical&nbsp;and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.</i></p>\n<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Medtech Trends That Will Outlive the Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Medtech Trends That Will Outlive the Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 10:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/3-medtech-trends-that-will-outlive-the-pandemic-2021-03-04","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138978257","content_text":"Vaccines are starting to roll out in many parts of the world and some believe the beginning of the end of the pandemic is in sight. Optimism is always welcome, but it’s important to acknowledge the challenges aren’t all behind us.\nNeither are the solutions to those challenges.\nInnovative and exciting medtech solutions emerged over the past year in attempts to address our pandemic-induced problems head on, particularly in the field of medical technology. Which of these technologies offer advantages that go beyond the inconveniences of social distancing, and provide permanent value once relative normality has returned?\nPatient Safety\nWhile increased awareness of patient safety has made major strides in the last decade, COVID-19 has thrown the issue into the spotlight. It was 2016 when BMJ published a report citing medical errors as the third leading cause of death in the United States behind heart disease and cancer. The medical community took a brief moment to pause and reflect on how a certain proportion of human loss, through human error, is something we as a society have traditionally accepted. Now, we’re reflecting on patient safety again.\nSocial distancing, viral prevention, sanitation, and refined approaches to ICU patients all came to the fore during the height of the pandemic. Malnourishment among ICU patients, for instance, was a much more obscure concern before the pandemic. But with a rising number of patients requiring ICU support alongside more studies highlighting the dangers of malnourishment, medtech providers have developed unique methods to circumvent these dangers.\nMedical communities have even cultivated awareness campaigns to streamline the issue, with projects like the Patient Safety Movement, which aims to raise public awareness, expand clinical support, and create a wider sense of urgency surrounding the issue. The movement works to create and freely share actionable solutions (Actionable Patient Safety Solutions) to help mitigate potential dangers.\nPublications such as the British Medical Journal had already red-flagged it as a serious concern long before the pandemic entered the frame. As such, the issue is unlikely to peter out once we’ve arrived at a point of greater normality.\nTelemedicine\nTelemedicine is the very epitome of technology-driven healthcare and serves as a literal lifeline for millions of people who do not have access to proper medical facilities.\nIn April of 2020, 43.5 percent of Medicare primary care visits utilized telehealth methods rather than in-person visits. One of the major benefits of telehealth over in-person alternatives is that it has reduced contact between patients, healthcare workers, and other patients—making it a fitting solution within social distancing guidelines. Wearable devices enable healthcare workers to have real-time information on patient data while they remain at home, such as physicians being updated remotely by people with diabetes regarding insulin dosages.\nTelemedicine will likely become part of the medtech furniture beyond the pandemic, since its benefits and usability achieved vindication through the necessity of circumstance.\nAccording to Mordor Intelligence, the industry will be worth more than $66 billion by 2021. It should be stressed that Telemedicine is not a product of 2020. It was being developed much prior and just like patient safety, the pandemic has acted as a wonderful springboard. In essence, telemedicine allows greater access to medical specialists while allowing medicine to treat more patients on a whole. Pandemic or no pandemic, this is a destination medicine will always strive for.\nDeep Tech\nDigital technology is undeniably altering the way care is both accessed and delivered. 2020 has been a catalyst for this sphere—necessity is the mother of invention, and there has been plenty of necessary demand as of late.\nDeeptech is the generic term designated for technologies not focused on end-user services that includes artificial intelligence, robotics, blockchain, and advanced material science, as well as photonics and electronics, biotech and quantum computing. Deeptech exists as a disruptor with a difference. We think about it as the technology that allows us to transcend the status quo, since current technologies ultimately block progress and deeptech is acting as the un-blocker.\nSwati Chaturvedi, CEO of Propel, put it succinctly in an interview with Medtech Innovation:\n“They are trying to solve big issues that really affect the world around them.. For example, a new medical device or technique fighting cancer.”\nDeep Tech has been taken by the travails of COVID-19, since the effects of the virus represent the most pressing priority for medtech going into the new year. But it would be a mistake to view Deep Tech as some temporary trend, it represents the first step for medtech in one of the most comprehensive transitions of our technological and functional capacities.\nIt would be easy to explain away medtech’s activity in 2020 as a direct result of Covid, with trends arising to to address the challenges. The truth is a large proportion of the trends we are seeing now have been in the pipelines for some time, some for decades. In some cases, it's taken extraordinary global circumstances for medical trends to propel, but now that the global mindset is becoming digitized, more demanding, and wearier of potential disaster, such trends are unlikely to depart any time soon. People are anesthetized by familiarity, and it requires a year of extreme trepidation for our mindsets to embrace unconventionally effective solutions.\nAbout Author\nDoron Besser, Chief Executive Officer: Doron Besser is the CEO of ENvizion Medical and Managing General Partner of Swing Medical. Prior to co-founding ENvizion with Shay Tsuker in 2013, Doron served as President and CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at SuperDimension, a leader in minimally-invasive pulmonology devices. Doron holds a Doctor of Medicine from Ludwig Maximillians University in Munich, Germany.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}